MedTrace Logo

Three-Vessel Versus Unilateral Antegrade Cerebral Perfusion in Emergency Total Arch Replacement for Acute Type A Aortic Dissection

NCT07043777 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 201

Last updated 2026-07-01

No results posted yet for this study

Summary

This single-centre retrospective observational cohort study describes the technical feasibility of direct three-vessel antegrade cerebral perfusion, designated modified antegrade cerebral perfusion (MACP), during emergency total arch replacement for acute type A aortic dissection. MACP delivers antegrade cerebral perfusion directly to the brachiocephalic, left common carotid, and left subclavian arteries. Outcomes are summarised descriptively and compared exploratorily with unilateral right axillary antegrade cerebral perfusion (uACP). Because perfusion strategy and treating surgeon were completely confounded, the comparative analyses are intended only to contextualise the technical experience and generate hypotheses.

Conditions

  • Acute Type A Aortic Dissection

Interventions

PROCEDURE

Direct Three-Vessel Antegrade Cerebral Perfusion (MACP)

Direct antegrade cerebral perfusion through balloon-tipped catheters inserted into the brachiocephalic, left common carotid, and left subclavian arteries during emergency total arch replacement.

PROCEDURE

Unilateral Right Axillary Antegrade Cerebral Perfusion (uACP)

Unilateral antegrade cerebral perfusion delivered through right axillary artery cannulation during emergency total arch replacement.

Sponsors & Collaborators

  • China Medical University Hospital

    lead OTHER

Principal Investigators

  • En-Bo Wu, M.D. · Department of Anesthesiology, China Medical University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2025-04-30
Completion
2025-06-01

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07043777 on ClinicalTrials.gov